The relationship between epilepsy and sexual dysfunction: a review of the literature

Muhammad Atif¹, Muhammad Rehan Sarwar¹* and Shane Scahill²

Abstract

Background and objectives: Regardless of the disease states that people suffer from, maintaining sexual function is an important indicator of quality of life. The objective of this review was to figure out the relationship between epilepsy, antiepileptic drugs (AEDs) and sexual dysfunction.

Results: In various epidemiological and clinical studies, epilepsy has been correlated with a reduction in sexual function. This sexual dysfunction is not always detected in epileptic patients until systematic efforts are put in place, as part of the assessment and treatment process. Therefore, precise evaluations of the incidence of treatment related sexual dysfunction in epileptic patients is still lacking.

Conclusions: This literature review concluded that sexual function is influenced by the pathophysiology of epilepsy, as well as through the use of AEDs. To maximize quality of care in patients with epilepsy and those patients with other disease states who receive AEDs, it is important to address the status of the patient’s sexual function as part of the initial routine assessment and with any treatment related follow-up. Minimizing the effects of AED related sexual dysfunction can be achieved by raising awareness among patients, providing education and training for physicians regarding sexual dysfunction and obtaining a baseline sexual history from the patient so are important recommendations. In addition, systematic studies are needed to explore the risk and mechanism of such treatment related side effects on sexual function.

Keywords: Epilepsy, Sexual dysfunction, Antiepileptic drugs, Epidemiology, Relationship

Background

Historically discussion around sexual practices and associated dysfunction was taboo. However, in the modern era, awareness of issues associated with sexual dysfunction has been more commonly aired. Western civilization has become more open-minded about discussing sexual dysfunction, and in particular about erectile dysfunction (ED) in men, often associated with chronic disease. With this opening up of society there has been encouragement for people to think about their sexual performance and to seek advice from health consultants (Laumann et al. 1999; Kaufman et al. 2015).

The very first orally available drug for male ED was sildenafil (Viagra) which not only treated the problem but also through marketing campaigns, increased awareness among people. These days ED is considered amongst the general public to be a “medical condition” that can be managed. In terms of etiology both physical (ED in men due to circulatory disorders) and psychological factors (inadequate interpersonal associations, psychiatric illness) are responsible for sexual dysfunction. Another cause of sexual dysfunction is the use of drugs such as anti-hypertensive (Fogari et al. 1998), anti-psychotics (Baldwin and Birtwistle 1997), anti-depressants (Baldwin et al. 1997; Goldstein and Goodnick 1998) and anti-epileptic drugs (AEDs) (Hamed et al. 2015; Kirmani et al. 2014; Lombardi et al. 2015; Meryn 2015; Svalheim et al. 2015; Urso et al. 2014; Kaufman et al. 2015; Sivaraaman...
and Mintzer 2011; Kaufman and Struck 2011b). The link between sexual dysfunction and drug induced as opposed to disease induced effects is complicated, and the case of epilepsy and AEDs has received less attention than one might expect. Sexual dysfunction may impact on compliance and is reported to be dose dependent with various AEDs (Kaufman and Struck 2011a). For example, case reports of gabapentin-induced sexual dysfunction suggest that the minimum total daily dose required for sexual dysfunction is 900 mg (Dalal and Zhou 2008; GRANT and OH 2002).

The human sexual response and sexual dysfunction

Natural sexual response of a human can be divided into four stages and disturbance can occur in any one these stages;

1. **Desire** typically this consists of fantasies about, and the desire to have, sexual activity.
2. **Excitement** the individual sense of sexual enjoyment, associated with physiological alterations, including penile tumescence and erection in men, and pelvic vasocongestion, inflamed external genitalia, and lubrication and extension of the vaginal canal in women.
3. **Orgasm** height of sexual enjoyment, by the discharge of sexual tension and rhythmic contraction of perineal muscles as well as reproductive organs.
4. **Resolution** sense of comfort and muscular leisure. Physiologically men are noncompliant to erection and orgasm for a varied time period, while women might be capable to respond to additional stimulation.

The label ‘sexual dysfunction’ has been classified in the International Classification of Mental and Behavioral Disorders, 10th edition (ICD-10) (World Health Organization 1992) (for those people who were incapable of enjoying their sexual relationship as they want). The ICD-10 sexual dysfunction categorization is not based on organic pathophysiology or infection. Both ICD-10 and Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) (American Psychiatric Association 2000) utilized the same classificatory proposal (Table 1).

| Table 1 Standard classification system for sexual dysfunction |
|-------------------------------------------------------------|
| F52.0  | Lack or loss of sexual desire |
| F52.1  | Sexual aversion and lack of sexual enjoyment |
| F52.2  | Failure of genital response |
| F52.3  | Orgasmic dysfunction |
| F52.4  | Premature ejaculation |
| F52.5  | Non-organic vaginismus |
| F52.6  | Non-organic dyspareunia |
| F52.7  | Excessive sexual drive |
| F52.8  | Other sexual dysfunction, not caused by organic disorder or disease |
| F52.9  | Unspecified sexual dysfunction, not caused by organic disorder or disease |

Epidemiology of sexual dysfunction

The epidemiology of sexual dysfunction has not been broadly discussed in the literature; or at least the literature has not been reviewed and synthesized. Thirty years ago prevalence data for sexual dysfunction were derived according to the DSM-III by Nathan et al., who analyzed twenty two studies about sexual dysfunction in the general population. Methodological issues in this analysis indicated that an extensive estimation might be made (Nathan 1986). The incidence of reduction of sexual desire was found to be 35% in women, 16% in men, premature ejaculation 35% and ED 10–20% in men and in female, orgasmic complication was found to be 5–15%. According to a study conducted in the United States (US), sexual dysfunction was more common in women (43%) than men (31%) (Laumann et al. 1999). In the case of women, low sexual desire (22% prevalence), arousal difficulty (14%) and sexual pain (7%) have been observed. Whilst for men premature ejaculation (21%), low sexual desire (5%) and ED (5%) have been observed. Sexual dysfunction rates can be different depending upon the population being studied and the nature of sexual dysfunction being evaluated. The data represented here demonstrates a high prevalence of sexual dysfunction for both males and females (Christensen et al. 2011; Ernst et al. 1993; Lindau et al. 2007; Hendrickx et al. 2016).
summarizes the key findings of studies published on sexual dysfunction among the general population.

The major categories of sexual dysfunction are influenced by various aspects. First, the means of enquiry and type of data reporting mechanism i.e. the occurrence of sexual dysfunction in one prospective study was 14% when relying on spontaneous self-reporting, but 58% when the doctor directly asked the patient about it (Montejo-Gonzalez et al. 1997). Second, the attitudes of people with respect to disclosing and fully discussing their sexual dysfunction issues with their physician is strongly influenced by the culture of a society (Bhavsar and Bhugra 2013).

To provide an example, this is especially the case with Muslim people whereby discussing anything sexually-related, including issues like sexual dysfunction outside of marriage is prohibited. This can make it very difficult for Muslim clients to seek help from health professionals; however, there mechanisms in place where it may be allowed for treatment purposes (Sungur and Bez 2016). Any sexual activity outside of marriage is also banned under Islam, but the religion encourages the enjoyment of sex and sensitivity to the needs of the spouse within heterosexual marriages. Therefore, it is critical for health professionals to be aware of the role of culture in defining sexual dysfunction and how cultural factors can be considered when initiating treatment as well as in therapeutic engagement and alliance between patient and practitioner.

Third, sexual dysfunction can be defined in many terms and is reliant on the belief of what is usual or normal in a sexual relationship (Bhugra and de Silva 2007). Finally, temporal trends can occur with spikes in concern about disorders, as increased awareness of sexual matters and availability of medical treatments increase the numbers who perceive themselves as suffering from sexual dysfunction and come forward to seek treatment (Baldwin 2001).
Children and adults are both affected by this disease. Approximately 1 in 26 people will develop epilepsy at some point in their lives (England et al. 2012). Sexual dysfunction associated with epilepsy is not yet completely understood (Harden 2008) and epilepsy is a complex disease causing several downstream pathological alterations which may need further exploration and treatment. One manifestation of the disease includes endocrine disorders in men and women which influences the reproductive system. Reproductive endocrine disorders in epileptic women include polycystic ovary syndrome (PCOS) (Bauer and Cooper-Mahkorn 2008; Bilo et al. 1988; Herzog et al. 2003a, b, 1984; Hopkinson et al. 1998; Gorkemli et al. 2008), hypothalamic amenorrhea (Bilo et al. 2001; Herzog et al. 1986b), hyperandrogenemia (HA) (Luef et al. 2002b; Löfgren et al. 2007), galactorrhea, hirsutism, menstrual abnormality and infertility (Bauer 2001; Bauer et al. 2002; Herzog et al. 2003b; Löfgren et al. 2006). Sexual dysfunction impacts between one and two thirds (30–66%) of epileptic men (Blumer and Walker 1967; Hierons and Saunders 1966; Herzog et al. 1986a) and between 14 and 50% of epileptic women (Demerdash et al. 1991; Jensen 1992). Evidence suggests that (Edwards et al. 1999; Baird et al. 2003; Quigg et al. 2002; Morrell et al. 2005) patients with partial epilepsy (PE) are more severely affected by reproductive endocrine and sexual dysfunction than idiopathic generalized epileptic (IGE) patients, predominantly of temporal lobe origin (Table 3).

The underlying mechanism of reproductive dysfunction has various hypotheses. One of the most accepted hypotheses suggests that the activity of gonadotropin-releasing hormone (GnRH) pulse generator is disturbed due to the temporal lobe regions associated with epilepsy, which might be the origin of paroxysmal release, just before the hypothalamus (Verrotti et al. 2015). Amplification of the pulse frequency of GnRH and as a result the luteinizing hormone (LH) and follicle-stimulating hormone (FSH) ratio is related among PCOS patients (Rauchenzauner et al. 2014). The decrease in GnRH pulse frequency also lowers LH and estrogen (E2) levels, which an attribute is of HA. Moreover, several other aspects, such as, obesity, genetic disposition, laterality of epilepsy, type of AED prescribed, age and severity of seizures, might also be reasons for clinical expression of specific reproductive disorders i.e. HA, PCOS, ovulation, hirsutism (Verrotti et al. 2011).

The relationship between sexual dysfunction and AEDs
Seizure disorders are linked with sexual dysfunction as part of the pathophysiology, whilst all the available AEDs have not yet been definitively proven to have negative impacts on sexual function. As such, evaluation of AED-induced sexual dysfunction is complicated and less than clear (Crenshaw and Goldberg 1996; Gitlin 2003). Comparative analyses of AEDs in patients with epilepsy, inducing sexual dysfunction are hard to find. The enzyme stimulating AEDs (phenytoin, topiramate, phenobarbital, oxcarbazepine and carbamazepine) raise hepatic synthesis of sex hormone binding globulin (SHBG) that lessens the accessibility of testosterone. Additionally, enhanced sex hormone metabolism and contraceptive hormones are not found with the use of AEDs that do not stimulate hepatic enzymes (e.g. lamotrigine, valproate, gabapentin, and vigabatrin) (Herzog et al. 2005; Morrell 2003). A consistent finding in the literature is that sexual dysfunction occurs with greater prevalence in patients taking phenytoin and carbamazepine than in patients taking valproate or lamotrigine (Herzog et al. 2005; Gutierrez et al. 2008). Women treated with valproate for bipolar disorder have also been reported to have severely decreased libido and anorgasmia, while there are case reports of gabapentin-associated anorgasmia in women who suffer from epilepsy (Harden 2005). A review of pregabalin efficacy and tolerability makes no mention of sexual dysfunction as an observed adverse effect (Tassone et al. 2007). Several studies in men and women have indicated that AEDs are related to sexual dysfunction (Table 4).

Antiepileptic drugs, epilepsy and serum sex hormones
Sex hormones levels contribute to sexual dysfunction as well as other reproductive disorders and these levels can be change as a result of the administration of AEDs (Table 5) (Morrell et al. 2005). The reproductive endocrine system may also be influenced by the pathophysiological effects of epilepsy as a disease in its own right (Scharfman et al. 2008). Endocrinological alterations due to epilepsy can be postulated in spite of the complicated interconnection among the limbic system and the hypothalamic–pituitary axis (HPA). Production toward HPA from the limbic cortex, containing nuclear configuration inside the amygdale, can alter key features in the discharge of sex hormones. Reproductive functions and discharge of sex hormones are affected by the influence of epilepsy in the medial temporal lobe region of the brain (Herzog et al. 1986b). Though the complexity it remains uncertain as to whether hormonal irregularity is because of epilepsy associated HPA dysfunction or whether it is due to the side effects of AEDs (Verrotti et al. 2011). The role of the HPA, the production of LH and FSH, GnRH, prolactin (PRL), and the end products of metabolism and their concentrations i.e. E2, T (testosterone), and DHEAS (dehydroepiandrosterone), are altered in epileptic women (Table 5) (Morrell 2003; Genton et al. 2001).
Treatment of sexual dysfunction

Appropriate treatment to be provided for epileptic patients with sexual dysfunction requires evaluation according to patient requirements, epileptic condition and comorbidities and the medicines available for managing epilepsy. Various approaches might be helpful for treatment of sexual dysfunction in epileptic patients including:

- Behavioral approaches to enhance sexual performance.
- Waiting for tolerance to develop.
- Dose reduction of current medicines.
- Drug administration delayed until after sex.

- Adjuvant treatment of the sexual dysfunction per se.
- Varying the diverse range of antiepileptic’s available for individual patients.

Several adjuvant medicines i.e. buspirone, yohimbine, neostigmine, cyproheptadine, mianserin, amantadine and dexamphetamine, are used to cure AEDs related sexual dysfunction (Shapira 2003). ED in men can be treated by using indicative approaches in combination with previously described treatment approaches. This might include corporal initiation of the penis to stimulate spinal reflexes, and loss of blood can be prevented by inserting elastic constricting bands at the base, and negative pressure facilitating cavernous blood flow.

### Table 3 Studies of epilepsy type and sexual and reproductive dysfunction

| Dysfunction assessed | Epilepsy type | Sex (n) | Prevalence | Sexual dysfunction assessment | References |
|----------------------|---------------|---------|------------|-------------------------------|------------|
| Sexual              |               |         |            |                               |            |
| i. Global anorgasmia| PE            | F (99)  | i. 17.9%   | Questionnaire                 | Morrell and Guldner (1996) |
| ii. Vaginismus      | IGE           | F (17)  | i. 31.3%   |                               |            |
| iii. Dyspareunia    |               |         | ii. 13.3%  |                               |            |
|                     |               |         | iii. 18.8% |                               |            |
| i. Sexual arousability| PE          | F (99)  | i. 72.2%   | Questionnaire                 | Lambert (2001) |
| ii. Sexual anxiety  | IGE           | F (17)  | i. 84.2%   |                               |            |
|                     |               |         | ii. 7.6%   |                               |            |
| Erectile dysfunction| GTCS          | M (25)  | 72%        | Questionnaire                 | Nikoobakht et al. (2007) |
|                     | PE            | M (16)  | 32%        |                               |            |
| Erectile dysfunction| PE            | M (418) | 25.8%      | Clinical interview            | Keller et al. (2012) |
|                     | IGE           | M (166) | 29.5%      |                               |            |
| Reproductive        |               |         |            |                               |            |
| i. Menstrual disorders| PE          | F (90)  | i. 44%     | Clinical examination, transvaginal ultrasonography | Löfgren et al. (2007) |
| ii. PCO             | IGE           | F (57)  | i. 29%     |                               |            |
| iii. HA             |               |         | ii. 28%    |                               |            |
| iv. PCOS            |               |         | iii. 13%   |                               |            |
|                     |               |         | iv. 19%    |                               |            |
| i. Menstrual disorders| IGE         | F (52)  | i. 23%     | Clinical examination, transvaginal ultrasonography | Luef et al. (2002a) |
| ii. Hirsutism       |               |         | ii. 5.8%   |                               |            |
| iii. PCO            | PE            | F (40)  | i. 42.5%   |                               |            |
|                     |               |         | ii. 2.5%   |                               |            |
|                     |               |         | iii. 37.5% |                               |            |
| PCO                 | IGE           | F (36)  | 21%        | Suprapubic ovary ultrasound   | Murialdo et al. (1997) |
|                     | PE            | F (65)  | 14.5%      |                               |            |
| i. Hypomenorrhoea   | IGE           | F (21)  | Overall results | Clinical examination | Demerdash et al. (1991) |
| ii. Amenorrhea      | PE            | F (106) | i. 22%     |                               |            |
| iii. Oligomenorrhoea|               |         | ii. 16%    |                               |            |
| iv. Polymenorrhoea  |               |         | iii. 9%    |                               |            |
|                     |               |         | iv. 2%     |                               |            |

PCO polycystic ovaries, HA hyperandrogenism, PCOS polycystic ovary syndrome, IGE idiopathic generalized epilepsy, PE partial epilepsy, F female
generated by using vacuum devices (Guldner and Morrell 1996). Additionally, methods such as the intercavernosal injection of vasodilators, i.e. papaverine or a grouping of papaverine, phentolamine, and prostaglandin E1, or yohimbine can be used to treat ED (Smaldone et al. 2004; Rokkas 2015). Other pharmaco-therapies for combatting ED to enhance the quality and frequency of erection include; topical nitroglycerine, topical minoxidil, and sildenafil (Rokkas 2015). The authors are not aware of any research that has been conducted on the use of sildenafil for ED in epileptic patients. Phosphodiesterase type-5 inhibitor drugs are now the first-line treatment for ED (Shamloul and Ghanem 2013; Bruzziches et al. 2013; Lee et al. 2015). Selective serotonin reuptake inhibitors (for example; escitalopram, paroxetine, fluoxetine, sertraline, etc.) and topical anesthetic creams are available but are not approved for the ED indication. However, they still serve as effective off-label treatments for premature ejaculation (Stimmel and Gutierrez 2006). Testosterone and aromatase inhibitors have been used in the investigational setting to treat sexual dysfunction in men taking AEDs (Hamed et al. 2013). Patient education and follow-up appointments are essential to ensure the optimal outcomes of pharmacologic treatment for sexual dysfunction in the epileptic patient. There are no approved pharmacologic treatments for female hypoactive sexual desire disorder or female orgasmic disorder. However, female sexual arousal disorder is treated with either estrogen replacement therapy or vaginal lubricants (Gutierrez et al. 2008).

**Conclusions and recommendations**

Sexual dysfunction in the epileptic patient is complex as it is often difficult to determine whether the dysfunction is disease or treatment related. There is a scarcity of data on the occurrence of sexual dysfunction

| Drug and dose (mg) | Dysfunction assessed | Sex (n) | Prevalence | Diagnosis | Sexual dysfunction assessment | References |
|-------------------|----------------------|--------|------------|-----------|------------------------------|------------|
| **Sexual dysfunctions** | | | | | | |
| Primidone (250) | Decreased libido or impotence | M (109) | 22% | GTCS | Questionnaire | Mattson et al. (1985) |
| Carbamazepine (580) | Sperm abnormality | M (13) | 77% | IGE, PE | Semen analysis and ultrasonography of testicles | Isojärvi et al. (2004) |
| Oxcarbazepine (1060) | Erectile dysfunction i. Premature ejaculation ii. Orgasm dysfunction iii. Diminished sexual desire | M (40) | 5% | PE | Clinical interview | Holskamp et al. (2005) |
| Valproate (1080) | | | | | | |
| Topiramate (100–200) | Erectile dysfunction | M (8) | i. 50% ii. 50% iii. 0.0% iv. 62.5% | GTCS | Sexual function questionnaire | Hamed et al. (2006) |
| Valproate (400–1250) | | | | | | |
| Carbamazepine (400–1000) | | | | | | |
| Pregabalin (150–600) | Erectile dysfunction | M (363) | 3.0% | PE | Questionnaire | Hitiris et al. (2006) |
| Lamotrigine (50–200) | Lack of sexual interest | M (75), F (66) | 11% | Complex PE, IGE | Changes in sexual functioning questionnaire (CSFQ) | Gil-Nagel et al. (2006) |
| Phenytoin (100) | Retrograde ejaculation | M (1) | Case report | PE | Clinical examination | Elia et al. (2010) |
| Zonisamide (200) | Erectile dysfunction | M (1) | Case report | PE | Clinical interview | Maschio et al. (2011) |
| Gabapentin (900) | Anorgasmia | F (1) | Case report | GTCS | Clinical interview | Perloff et al. (2011) |
| Leviteracetam (2000–5000) | i. Decreased libido ii. Erectile dysfunction iii. Anhedonia | M (2) | Case reports | GTCS, Myoclonic seizures | Clinical interview | Calabrò et al. (2012) |
| Pregabalin (300) | Anorgasmia | M (4) | Case reports | PE | Clinical interview | Calabrò et al. (2013) |
| Leviteracetam (500–1000) | Sperm abnormality | M (10) | 69.2% | GTCS, complex PE | Computer-aided sperm analysis | Xiaotian et al. (2013) |
| Valproate (500–1000) | i. Loss of libido ii. Erectile dysfunction | M (15) | 18.8% | Simple and complex seizures | Clinical examination | Calabro (2016) |
| Lacosamide (400) | | | | | | |

GTCS generalized tonic–clonic seizure, PE partial epilepsy, IGE idiopathic generalized epilepsy
Table 5  Serum sex hormone and sex hormone-binding globulin (SHBG) concentrations in various studies

| AEDs                          | Sex (n) | SHBG | T  | FT  | DHEAS | DiT | FAI | E2  | A    | Comments                                                                 | References                  |
|-------------------------------|---------|------|----|-----|-------|-----|-----|-----|------|----------------------------------------------------------------------------|----------------------------|
| Carbamazepine, valproate      | M (37)  | ↑    | ↓  | ↓   | NA    | NA  | NA  | NA  | NA   | Libido and fertility are low in epileptic patients                         | Dana-Haeri et al. (1982)   |
| Carbamazepine, valproate,     | M (72)  | ↑    | ↑  | ↓  | ↓    | ↑   | NA  | ↓   | NA   | —                                                                          | Toone et al. (1983)        |
| phenobarbital                  |         |      |    |     |       |     |     |     |      | Induces changes in circulating androgen concentrations                      | Connell et al. (1984)      |
| Carbamazepine                  | M (06)  | ↑    | ↑  | ↓  | ↓    | NA  | NA  | NA  | NA   | —                                                                          |                            |
| Phenytoin                      | M (20)  | NA   | ↑  | ↓  | NA    | NA  | NA  | NA  | NA   | Reductions in free testosterone serum levels are associated with TLE in men | Herzog et al. (1986a)      |
| Carbamazepine                  | F (23)  | ↑    | ➞  | ➞  | ↓    | NA  | NA  | NA  | NA   | 1 year prospective data                                                   | Isojärvi (1990)            |
| Carbamazepine                  | M (21)  | ↑    | ➞  | ➞  | NA    | NA  | ↓   | NA  | NA   | 1 year prospective study                                                  | Isojärvi et al. (1991)     |
| Carbamazepine                  | F (32)  | ↑    | ➞  | ➞  | NA    | NA  | NA  | ➞  | NA   | Low estradiol/SHBG ratios associated with menstrual disorders              | Isojarvi et al. (1995)     |
| Carbamazepine, phenytoin,     | M (37)  | ↑    | ➞  | ➞  | NA    | NA  | ↓   | NA  | NA   | Increased T/E2 ratio associated with hyposexuality                        | Muraldo et al. (1995)      |
| phenobarbital                  |         |      |    |     |       |     |     |     |      | High SHBG levels associated with diminished potency                         |                            |
| carbamazepine                  | M (25)  | ↑    | ➞  | ➞  | NA    | NA  | NA  | ➞  | NA   | —                                                                          | Isojarvi et al. (1995)     |
| Valproate, carbamazepine       | F (65)  | ↓    | ↑  | NA  | NA    | NA  | NA  | ➞  | NA   | T concentration is more elevated in women initiating treatment at the age <20 years | Isojärvi et al. (1996)     |
| Carbamazepine                  | F (23)  | ➞    | ↓  | NA  | NA    | NA  | ➞  | NA  | NA   | —                                                                          | Muraldo et al. (1998)      |
| Valproate                      | F (41)  | ➞    | ↑  | NA  | NA    | NA  | ➞  | NA  | NA   | Pre-pubertal, pubertal and Post-pubertal girls aged 8–18 year              | Vainionpää et al. (1999)   |
| Valproate                      | F (10)  | ↑    | ↑  | NA  | NA    | NA  | ➞  | ➞  | ➞   | 3 month prospective study                                                 | Rättäy et al. (2001)       |
| Carbamazepine, lamotrigine,    | M (70)  | ➞    | ➞  | NA  | NA    | ↑   | NA  | NA  | NA   | AEDs induce changes in circulating androgen concentrations                 | Mikkonen et al. (2004)     |
| valproate, oxcarbazepine       |         |      |    |     |       |     |     |     |      | AEDs induce changes in circulating androgen concentrations                 |                            |
| Carbamazepine                  | F (25)  | ➞    | NA  | NA  | NA    | ➞  | ➞  | ➞  | ➞   | Low E2/SHBG ratio is not associated with menstrual disorders              | Löffgren et al. (2006)     |
| Valproate, leviteracetam       | M/F (20)| ➞    | NA  | NA  | NA    | ➞  | NA  | ➞  | ➞   | —                                                                          | Rauchenzauner et al. (2010) |
| Topiramate                     | M (36)  | NA   | ↑  | ↓  | ↓    | NA  | NA  | NA  | ↓    | Hormonal changes are associated with sexual dysfunction                   | Urso et al. (2014)         |
| Primidone                      | M/F (20)| ↑    | ↓  | NA  | NA    | NA  | NA  | NA  | NA   | Leads to infertility in epilepsy patients                                  | Luef and Madersbacher (2015) |
| Lacosamide                     | M (10)  | ↓    | ↑  | NA  | NA    | NA  | ↑   | NA  | NA   | Cause deinduction of CYP enzymes                                          | Elger et al. (2016)        |

AEDs anti-epileptic drugs, M male, F female, T testosterone, DHEAS dehydroepiandrosterone, DiT dihydrotestosterone, FT free testosterone, FAI free androgen index (100 × T/SHBG), E2 estradiol, A androstenedione, TLE temporal lobe epilepsy, NA not available

≠, unchanged; ↑, increased; ↓, decreased
among the population as a whole and amongst those taking AEDs which can induce sexual dysfunction. This is a broad review looking at sexual dysfunction but the primary aim is to better understand the literature surrounding sexual dysfunction in the epileptic patient where both the pathophysiology and the treatment can cause a degree of sexual dysfunction. This review concluded that the most common sexual dysfunction in males is ED and early ejaculation while females complain of lack of interest in sex and failing to reach orgasm.

Epilepsy is associated with sexual dysfunction while it is not yet known whether all AEDs have a negative impact on sexual function. Unraveling the causations of AED-induced sexual dysfunction in the epileptic patient is complicated. Sex hormone levels can be changed due to AEDs which are the cause of sexual dysfunction and reproductive disorders. Systematic studies are needed to explore the risks and mechanisms of such treatment related side effects on sexual function, particularly in epileptics. This review lead to the following recommendations for physicians in improving the management of sexual dysfunction for their patients: (1) improved electronic medical record template to include appropriate questions related to sexual dysfunction in appropriate populations such as epileptics; (2) revision of undergraduate and residency curricula to include a broader appreciation of the impact of illness processes, comorbidities, and associated pharmacotherapies upon sexual functioning; and (3) required continuing medical education on sexual dysfunction.

Abbreviations
AEDs: antiepileptic drugs; ED: erectile dysfunction; ICD-10: International Classification of Mental and Behavioral Disorders, 10th edition; DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, fourth edition; DHEAS: dehydroepiandrosterone; D: dihydrotestosterone; FT: free testosterone; FAI: free androgen index; E2: estradiol; A: androstenedione; TLE: temporal lobe epilepsy; PE: phosphodiesterase type 5 inhibitors; FT: free testosterone; FAI: free androgen index; E2: estradiol; A: androstenedione; TLE: temporal lobe epilepsy; PE: phosphodiesterase type 5 inhibitors.

Authors’ contributions
MAT, MRS and SS contributed in the concept and design of this review article. MRS did the literature search. MAT and SS critically revised the paper for important intellectual content. All authors read and approved the final manuscript.

Author details
1 Department of Pharmacy, The Islamia University of Bahawalpur, Bahawalpur, Punjab, Pakistan. 2 School of Management, Massey University, Auckland, New Zealand.

Acknowledgements
None.

Competing interests
The authors declare that they have no competing interests.

Received: 18 March 2016 Accepted: 26 November 2016
Published online: 02 December 2016

References
American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, text revision (DSM-IV-TR). American Psychiatric Association, Washington, DC
Atif M, Azeem M, Sarwar MR (2016) Potential problems and recommendations regarding substitution of generic antiepileptic drugs: a systematic review of literature. SpringerPlus 5(1):1
Baird AD, Wilson SJ, Bladin PF, Saling WM, Reynolds DC (2003) Sexual outcome after epilepsy surgery. Epilepsy Behav 4(3):268–278
Baldwin DS (2001) Depression and sexual dysfunction. Br Med Bull 57(1):81–99
Baldwin D, Birtwistle J (1997) Schizophrenia, antipsychotic drugs and sexual function. Primary Care Psychiatry 3:115–124
Baldwin DS, Thomas SC, Birtwistle J (1997) Effects of antidepressant drugs on sexual function. Int J Psychiatry Clin Pract 1(1):47–58
Bancroft J (2009) Human sexuality and its problems. Elsevier Health Sciences, Amsterdam
Bauer J (2001) Interactions between hormones and epilepsy in female patients. Epilepsia 42(s3):20–22
Bauer J, Cooper-Mahkorn D (2008) Reproductive dysfunction in women with epilepsy: menstrual cycle abnormalities, fertility, and polycystic ovary syndrome. Int Rev Neurobiol 83:135–155
Bauer J, Isosjärvi J, Herzog A, Reuber M, Polson D, Taubell E, Genton P, Van Der Ven H, Roos SG, Lefèvre F (2002) Reproductive dysfunction in women with epilepsy: recommendations for evaluation and management. J Neurol Neurosurg Psychiatry 73(2):121–125
Bhavsar V, Bhuga D (2013) Cultural factors and sexual dysfunction in clinical practice. Adv Psychiatr Treat 19(2):144–152
Bhuga D, de Silva P (2007) Sexual dysfunction across cultures. In: Textbook of cultural psychiatry. pp 364–378
Bilo L, Meo R, Nappi C, Annunziato L, Striaio S, Colao AM, Merola B, Buscaino GA (1998) Reproductive endocrine disorders in women with primary generalized epilepsy. Epilepsia 29(5):612–619
Bilo L, Meo R, Valentino R, Di Carlo C, Striaio S, Nappi C (2001) Characterization of reproductive endocrine disorders in women with epilepsy. J Clin Endocrinol Metab 86(7):2950–2956
Blumner D, Walker AE (1967) Sexual behavior in temporal lobe epilepsy: a study of the effects of temporal lobectomy on sexual behavior. Arch Neurol 16(1):37–43
Bruzziches R, Franchonno D, Gareno L, Benzi A, Aversa A (2013) An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors. Expert Opinion Pharmacother 14(10):1333–1344
Burr A, Specter T (2011) Recent and lifelong sexual dysfunction in a female UK population sample: prevalence and risk factors. J Sex Med 8(9):2420–2430
Calabro R (2016) Sexual dysfunction: case report. Reactions 1583:669
Calabrò RS, Italiano D, Militi D, Bramanti P (2012) Levetiracetam-associated loss of libido and anhedonia. Epilepsia Behav 24(2):283–284
Calabrò RS, De Luca R, Pollicino P, Bramanti P (2013) Anorgasmia during pregabalinal add-on therapy for partial seizures. Epileptic Disord 15(3):358–361
Christensen BS, Gronhøk M, Olmer M, Pedersen BV, Graugaard C, Frisch M (2011) Sexual dysfunctions and difficulties in Denmark: prevalence and associated sociodemographic factors. Arch Sex Behav 40(1):121–132
Connell J, Rapoport W, Beastall G, Brodie M (1984) Changes in circulating androgens during short term carbamazepine therapy. Br J Clin Pharmacol 17(3):347–351
Crenshaw TL, Goldberg JP (1996) Sexual pharmacology: Drugs that affect sexual functioning. WW Norton & Co, New York
Dalal A, Zhou L (2008) Gabapentin and sexual dysfunction: report of two cases. Neurologist 14(1):50–51
Dana-Haeri J, Oxley J, Richens A (1982) Reduction of free testosterone by antiepileptic drugs. BMJ 284(6309):85–86
Demerdash A, Shaalan M, Miedani A, Kamel F, Bahri M (1991) Sexual behavior of a sample of females with epilepsy. Epilepsia 32(1):82–85
Edwards HE, Burnham WM, Ng MM, Asa S, MacLusky NJ (1999) Limbic seizures alter reproductive function in the female rat. Epilepsia 40(10):1370–1377
Elger CE, Rademacher M, Brandt C, Elmoufti S, Dedeken P, Eckhardt K, Tennigkeit F, De Backer M (2016) Changes in hormone and lipid levels in male patients with focal seizures when switched from carbamazepine to lacosamide as adjunctive treatment to levetiracetam: a small phase IIIb, prospective, multicenter, open-label trial. Epilepsy Behav 62:1–5
Maschio M, Saveriano F, Dinapoli L, Jandolo B (2011) Reversible erectile dysfunction in a patient with brain tumor-related epilepsy in therapy with zonisamide in add-on. J Sex Med 8(12):3515–3517

Mattson RH, Cramer JA, Collins JF, Smith DB, Delgado-Escueta AV, Browne TR, Williamson PD, Treiman DM, McNamara JD, McCutchen CB (1985) Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic–clonic seizures. N Engl J Med 313(3):145–151

McCabe MP, Sharlip ID, Lewis R, Atalla E, Balon R, Fisher AD, Laumann E, Lee SW, Segraves RT (2016) Incidence and prevalence of sexual dysfunction in women and men: a consensus statement from the Fourth International Consultation on Sexual Medicine 2015. J Sex Med 13(2):144–152

Meryn S (2015) Erectile dysfunction in the elderly. Springer, Berlin, pp 159–166

Mialon A, Berchtold A, Michaud P-A, Gmel G, Suris J-C (2012) Sexual dysfunctions among young men: prevalence and associated factors. J Adolesc Health 51(1):25–31

Mikkonen K, Tapanainen J, Pafvanaho M, Isojarvi JI, Vainionpaa LK (2004) Serum androgen levels and testicular structure during pubertal maturation in male subjects with epilepsy. Epilepsia 45(7):769–776

Montejo-Gonzalez AL, Llorca G, Izquierdo J, Ledesma A, Bousono M, Calcedo A, Carrasco J, Ciudad J, Daniel E, De La Gandara J (1999) Fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther 23(3):176–194

Morrell MJ (2003) Reproductive and metabolic disorders in women with epilepsy. Epilepsia 44(4):11–20

Morrell MJ, Guldner GT (1996) Self-reported sexual function and sexual arousability in women with epilepsy. Epilepsia 37(12):1204–1210

Morrell MJ, Flynn KL, Dohe S, Fletter E, Kalayjian L, Pack AM (2005) Sexual dysfunction, sex steroid hormone abnormalities, and depression in women with epilepsy treated with antiepileptic drugs. Epilepsy Behav 6(3):360–365

Muralidoro G, Galimberti CA, Fonzi S, Manni R, Costelli P, Parodi C, Solinas GP, Meryn S (2015) Erectile dysfunction, sex steroid hormone abnormalities, and depression in women with epilepsy treated with antiepileptic drugs. Epilepsy Behav 64(6):687–697

Nikoobakht M, Motamedi M, Orandi A, Meysamie A, Emamzadeh A (2007) Antiepileptic drugs, sex hormones, and PCOS. Epilepsia 52(2):199–211

Nikooabadi M, Motamedi M, Onandi A, Meysamie A, Emarzadeh A (2007) Sexual dysfunction in epileptic men. Urol J 4(2):111–117

Osborn M, Hawton K, Gath D (1988) Sexual dysfunction among middle aged women in the community. BMJ 296(6627):959–962

Perloff MD, Thaler DE, Otis JA (2011) Anorgasmia with gabapentin may be common in older patients. Am J Geriatr Pharmacother 9(3):199–203

Quigg M, Kiley JM, Shneker B, Veldhuis JD, Bertram EH (2002) Interictal and postictal alterations of pulsatile secretions of luteinizing hormone in temporal lobe epilepsy in men. Ann Neurol 51(S1):S59–S66

Rattya J, Pakarinen AJ, Knip M, Repo-Outakoski M, Myllyla VV, Isojarvi JI (2001) Early hormonal changes during valproate or carbamazepine treatment: a 3-month study. Neurology 57(3):440–444

Rauchenzauner M, Bitsche G, Svalheim S, Taubell E, Haberlandt L, Wildt L, Rosta T, Luef G (2010) Effects of levetiracetam and valproic acid monotherapy on sex-steroid hormones in prepubertal children—results from a pilot study. Epilepsy Res 88(2):264–268

Rauhelenauner M, Rosea S, Prietsch M, Wildt L, Haberlandt E, Baumann M, Rosta T, Agostinelli S, Pizzolorusso A, Luef G (2014) Reproductive endocrine health in pubertal females with epilepsy on antiepileptic drugs: time to screen? Neuropediatrics 45(4):226–233

Rokkas K (2015) Management of erectile dysfunction beyond PDE-5 inhibitors. Springer, Berlin, pp 195–203

Safarnejad M (2006) Female sexual dysfunction in a population-based study in Iran: prevalence and associated risk factors. Int J Impot Res 18(4):382–395

Schafarik HE, Kim M, Hintz TM, MacLusky NJ (2008) Seizures and reproductive function: insights from female rats with epilepsy. Ann Neurol 64(6):687–697

Shamloul R, Gharem H (2013) Erectile dysfunction. Lancet 381(9861):153–165

Shapira N (2003) Methods of treating medication-, substance-, disease-, and other medical condition-related sexual dysfunction. Google Patents

Sivaraaman K, Mintzer S (2011) Hormonal consequences of epilepsy and its treatment in men. Curr Opin Endocrinol Diabetes Obes 18(3):204–209

Smaldone M, Sukkanerth R, Reda A, Khan A (2004) Epilepsy and erectile dysfunction: a review. Seizure 13(7):453–459

Stimmel GL, Gutierrez MA (2006) Pharmacologic treatment strategies for sexual dysfunction in patients with epilepsy and depression. CNS Spectr 11(5):31–37

Sungur MZ, Bez Y (2016) Cultural factors in the treatment of sexual dysfunction in Muslim clients. Curr Sex Health Rep 8(2):57–63

Svalheim S, Sveberg L, Mochol M, Taubell E (2015) Interactions between antiepileptic drugs and hormones. Seizure 28:12–17

Tassone DM, Boyce E, Güner Y, Nuzum D (2007) Pregabalin: a novel y-amino-butyric acid analogue in the treatment of neuropsychiatric pain. CNS Spectr 12(5):26–48

Toone B, Wheeler M, Nanjee M, Fenwick P, Grant R (1983) Sex hormones, sexual activity and plasma anticonvulsant levels in male epileptics. J Neurol Neurosurg Psychiatry 46(6):824–826

Ursi L, Zumo M, Gammino M, Fierro B, Pavone C, Daniele O (2014) Antiepileptic drugs, sexual functions and serum hormonal profile in males with epilepsy. Med Surg Urol 3:130. doi:10.4172/2168-9857.1000130

Vainionpaa LK, Rättyä J, Knip M, Tapanainen JS, Pakarinen AJ, Lanning P, Tekay M, Urso L, Zummo L, Gammino M, Fierro B, Pavone C, Daniele O (2014) Antiepileptic drugs, sex hormones, and PCOS. Epilepsia 55(2):199–211

Verrotti A, D'Agicio D, Mohn A, Coppola G, Parisi P, Chiarelli F (2011) Antiepileptic drugs, sex hormones, and PCOS. Epilepsia 52(2):199–211

Verrotti A, Prezioso G, D'Agicio C, Belcastro V (2015) Reproductive hormones in epilepsy therapy: from old promises to new hopes. In: Epilepsy towards the next decade. Springer, Berlin, pp 201–211

World Health Organization (1993) The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. World Health Organization, Geneva

Xiaotian X, Hengzhong Z, Yao X, Zhipan Z, Daoliang X, Yumei W (2013) Effects of carbamazepine on sexual function and sperm parameters in Chinese Han men with epilepsy. J Sex Med 10(6):1618–1625

Xiong T, Du X, Shi L, Fan C, Ge J, Ji Q, Yuan W (2015) Reproductive endocrine function in a patient with brain tumor-related epilepsy in therapy with zonisamide in add-on. J Sex Med 8(12):3515–3517

Yilmaz Ö, Ceylan C, Mirtaş Ö, Akdemir T, Fราช along others (2011) The epidemiology of the DSM-III psychosexual dysfunctions. J Sex Marital Ther 12(4):267–281

Zhang X, Shang Y, Ding J, Tan W, Yin H, Li X (2017) Antiepileptic drugs and hormones. Seizure 28:12–17.